MSM Eye Drops: Do They Work? Evidence, Safety and FDA Warnings

Blog

MSM Eye Drops: Do They Work? Evidence, Safety and FDA Warnings

August 22, 2026

MSM eye drops are not approved for any eye condition, and we found no published controlled human trial testing them. On 22 August 2023 the FDA warned against two brands, Dr. Berne's MSM Drops 5% Solution and LightEyez MSM Eye Drops, after its tests found contamination. It says no legally marketed eye drug contains MSM as an active ingredient.

Most MSM research is oral and unrelated to the eye. This page reviews what that research shows, what the FDA found, and what to ask before putting anything in your eye.

The FDA warning in brief. In August 2023 the FDA told consumers not to buy or use Dr. Berne's MSM Drops 5% Solution, which tested positive for bacteria and fungi, or LightEyez MSM Eye Drops – Eye Repair, which tested positive for bacteria. Earlier that year, in March 2023, Pharmedica USA recalled Purely Soothing 15% MSM Drops because they were not sterile, and after the August warning Dr. Berne's recalled its MSM drops. Contaminated eye drops can cause infections that threaten sight. If you have used MSM drops and have pain, redness, discharge or blurred vision, stop and see an eye doctor promptly.
Written for patients and families. This is the plain-language edition. Eye-care professionals may prefer the referenced version: MSM Eye Drops: An Evidence Review for Eye-Care Professionals.

Key Takeaways

  • The FDA states that there are no legally marketed ophthalmic drugs that contain MSM as an active ingredient.
  • Most MSM research is oral and concerns musculoskeletal outcomes. The three studies most often cited as ocular evidence used MSM as a permeability enhancer for a chelating agent in rats, and in the raised-pressure model that combination did not lower intraocular pressure.
  • In 2023 the FDA warned consumers about two specific marketed MSM eye-drop products after testing found contamination, and a third company recalled its MSM drops for non-sterility. Those findings concern the products tested. They do not establish that every MSM product is contaminated.
  • Anything placed in the eye must meet a high standard for sterility, formulation and manufacturing, and reaching the retina or optic nerve from a topical drop is genuinely difficult.
  • Netra Restoration Therapy has not been evaluated in controlled trials. Published research supports the plausibility of individual mechanisms but does not demonstrate through clinical trials that the programme changes the course of any eye disease.
  • Nothing here replaces the care your ophthalmologist directs.

For the condition as a whole, including the types, the symptoms that need prompt care, the causes, how it is diagnosed, today’s treatments, whether it can be cured and the trials under way, read our dry eye guide.

This article is general education, not medical advice. If you are being treated for glaucoma, macular degeneration, diabetic retinal disease or any other eye condition, continue the care your ophthalmologist has prescribed and speak with them before adding anything. Do not reduce or stop prescribed drops, injections, laser treatment or scheduled monitoring on the basis of anything you read here.

The question that actually matters

People who have watched their vision change, and who have been told there is nothing further to do, often arrive at an appointment with a bottle in hand. Increasingly it is a bottle of MSM eye drops.

The question they ask is whether the ingredient works. It is a reasonable question, and it is the wrong one, or at least it is three questions compressed into one, and separating them changes the answer.

Has this specific, sterile product been shown to reach the tissue it is meant to act on? Does it improve an outcome a person would actually notice? And does it stay safe with repeated use over years, rather than weeks?

Most eye products sold directly to consumers have never been asked any of the three. That is not an accusation aimed at any company. It is a description of how this part of the market works, and understanding it is more useful than a verdict on any single ingredient.

What MSM is, and what the research actually studied

Methylsulfonylmethane, or MSM, also called dimethyl sulfone, is a small organosulfur compound. It has a real scientific literature, and it is worth being precise about what that literature covers.

Most of it is oral. Human trials have focused on musculoskeletal outcomes: knee osteoarthritis, exercise recovery. Reviews describe proposed anti-inflammatory and antioxidant effects and a generally favourable short-term safety profile at the doses studied by mouth. Laboratory work has reported effects on inflammatory signalling in cultured cells; animal work has examined oral toxicology and distribution.

None of that transfers automatically to a drop. Route of administration changes exposure, tissue concentration, metabolism, formulation requirements and risk. Oral tolerability cannot establish corneal safety. A systemic anti-inflammatory signal cannot demonstrate that anything reached the retina after a drop landed on the surface of the eye.

The ocular studies are not what they are often taken to be

Three animal studies are frequently cited as evidence that MSM eye drops have direct ocular support. They deserve a careful reading.

In those experiments, MSM was used as a permeability enhancer, a vehicle to help a chelating agent, EDTA, penetrate ocular tissue in rats. The combination was then evaluated in rat models of elevated intraocular pressure and diabetic cataract. MSM was the delivery aid, not the therapy under test.

One detail from that work is directly relevant to how MSM drops are marketed for glaucoma. In the raised-pressure model, the EDTA and MSM combination reduced markers of oxidative and inflammatory damage without changing intraocular pressure at all. The most frequently cited animal evidence for MSM in glaucoma is, on inspection, evidence that the combination did not lower pressure.

It is also worth saying that enhanced penetration is not automatically a benefit. Increasing how much of a formulation crosses into the eye increases exposure of sensitive tissue to everything in the bottle: the active ingredient, the excipients, any impurities, and any contaminants.

One case report worth knowing about

A published case report describes bilateral acute angle closure in an otherwise healthy 35-year-old woman who had started several MSM-containing oral supplements at the same time; it resolved within four days of stopping them. The authors proposed a sulfonamide-like idiosyncratic mechanism.

A single case with several simultaneous exposures cannot establish causation or quantify risk, and it does not concern eye drops. It does illustrate a broader point: a widely consumed compound is not automatically inert.

What the FDA has said

The position of the agency is a matter of public record, and it is worth quoting rather than paraphrasing. The FDA states that there are no legally marketed ophthalmic drugs that contain MSM as an active ingredient. That statement appears in the 2023 consumer alert and remains on the consumer eye-drops page, last refreshed in June 2026.

Timeline of FDA actions on MSM eye drops

In short: no MSM eye drop is FDA-approved. Between March 2023 and February 2024, two brands were recalled, the FDA warned consumers about two contaminated brands, and two companies received FDA warning letters.

FDA actions on MSM eye drops, 2023 to 2026. Checked against FDA records on 24 October 2026.
DateWhat happened
3 March 2023Company recall: Pharmedica USA. Purely Soothing 15% MSM Drops, recalled worldwide because the drops were not sterile.
22 August 2023FDA consumer warning. Do not buy or use Dr. Berne's MSM Drops 5% Solution (bacteria and fungi found) or LightEyez MSM Eye Drops – Eye Repair (bacteria found). The FDA also stated that no legally marketed eye drug contains MSM as an active ingredient.
26 August 2023Company recall: Dr. Berne's Whole Health Products. MSM Drops 5% and 15% Solution, Organic Castor Oil Eye Drops and MSM Mist, after FDA testing found contamination in a lot of the 5% drops.
22 November 2023FDA warning letter to Dr. Berne's Whole Health Products. MSM eye drops and an eye mist sold with disease-treatment claims and no FDA approval, and a contaminated lot distributed.
15 February 2024FDA warning letter to LightEyez Limited. Microbial contamination in its MSM Eye Repair Drops, manufacturing failures, and eye drops sold as unapproved new drugs.
15 June 2026FDA consumer page update. The FDA's page on eye drops still says that no legally marketed eye drug contains MSM as an active ingredient.

In August 2023 the FDA warned consumers not to use two specific marketed MSM eye-drop products after agency testing found bacterial contamination in both and fungal contamination in one. Warning letters to both firms followed. Separately, a third company recalled its MSM drops earlier that year for non-sterility, a recall the FDA classified in its most serious category.

Two things follow, and the difference between them matters.

Those findings condemn the products that were tested and recalled. They do not establish that every bottle containing MSM is contaminated, and nobody should suggest otherwise.

The durable point is the category-level one. No MSM ophthalmic product has been through a process in which effectiveness, safety, quality and labelling were established and reviewed.

Why a product can be on sale without any of that

Market presence is not the same as approval. A company can place a product into commerce before the FDA has inspected it or taken any action. Agency oversight combines premarket requirements with postmarket surveillance, inspections, sampling, adverse-event reports, warning letters, import actions and recalls, resources allocated by risk, on a timeline that is neither instant nor a verdict on what came before.

Labelling does not change the category, either. A product intended to treat, mitigate or prevent disease is regulated as a drug regardless of whether it is described as natural, homeopathic, traditional, or a supplement. Dietary-supplement rules govern things that are swallowed. They do not govern products placed in the eye.

Why anything going in the eye faces a higher bar

A drop bypasses defenses the rest of the body has, and it contacts tissue that does not regenerate the way skin does, repeatedly, often for years.

A safe ophthalmic product must be sterile throughout its shelf life and every use, with controlled particulate and endotoxin burden, tolerable pH and osmolality, ophthalmically appropriate excipients, a reproducible delivered dose, and packaging that protects the formulation from the first drop to the last.

None of that is paperwork. Published studies repeatedly document microbial contamination of multidose ophthalmic containers in clinical and patient-use settings, and contaminated solutions have been linked to serious corneal infection for decades. The 2023 outbreak of extensively drug-resistant Pseudomonas aeruginosa traced to a preservative-free imported artificial tear is the modern reference case: 81 patients across 18 states, four deaths within thirty days among those with clinical cultures, four eyes removed, and fourteen patients with vision loss. That product contained no exotic active ingredient. It failed on manufacturing.

Preservatives are part of this picture and are often misunderstood. They reduce microbial growth in multidose containers, and chronic exposure to some of them, benzalkonium chloride in particular, can affect the ocular surface in susceptible patients. But preservative-free systems do not remove the contamination problem; they relocate it to single-use packaging or validated closure technology. Preservative-free on a label is not a safety claim. It tells you which of two problems the manufacturer chose to solve.

And getting to the back of the eye is genuinely hard

Tear turnover, blinking, nasolacrimal drainage, the corneal barrier, conjunctival absorption into the bloodstream, and the blood-ocular barriers all work against a topically applied molecule reaching the retina or optic nerve at a meaningful concentration.

A drop can coat the surface, feel soothing, and never approach a therapeutic concentration in the tissue it is advertised to help. An entire field of ophthalmic formulation research exists because this is difficult. So a claim that a simple topical solution reaches the macula, the optic nerve or the vitreous is a pharmacokinetic claim, and it needs pharmacokinetic evidence rather than analogy.

What a supervised, multi-target care model is, and what it is not

We should apply the same standard to our own work, so here it is plainly.

Netra Restoration Therapy is not a bottle and not a single pathway. It is a practitioner-supervised, individualized programme, designed to complement, never to replace, standard ophthalmic care. Its scientific rationale draws on research into ocular perfusion, oxidative stress, mitochondrial function, neuroinflammation, neurotrophic signalling and related pathways, on the reasoning that chronic retinal and optic-nerve disorders involve several interacting processes rather than one isolated mechanism.

What supervision adds is specific and checkable. A clinician can confirm the diagnosis and its urgency and screen for symptoms needing same-day attention. They can review every prescribed drug, over-the-counter product and supplement for interactions, including anticoagulant and antiplatelet risk, pregnancy, liver or kidney disease, and planned surgery. They can establish baseline measurements and repeat them on a defined schedule: visual acuity, contrast sensitivity, visual fields, intraocular pressure, optical coherence tomography. And they can interpret those measurements against what is known about their variability.

That last point is where most of the value sits. In the Ocular Hypertension Treatment Study, 86% of visual field abnormalities detected during follow-up were not confirmed on repeat testing. For structural imaging, the between-visit tolerance limit for average retinal nerve fibre layer thickness is roughly 3.9 microns. Those numbers cut both ways: they are why a patient should not be alarmed by one poor test, and equally why nobody should be reassured by one good one, or by feeling better after a week. A programme that treats every fluctuation as a response is not measuring anything.

Treatment that is measured can be modified, or stopped, or escalated to the treating ophthalmologist. A bottle cannot do any of that.

What is not established

An article like this is only worth reading if it says what it cannot support. So:

  • No controlled trial has evaluated the complete NRT protocol, and no head-to-head trial compares it with MSM eye drops or with usual care.
  • Published research supports the biological plausibility of individual mechanisms and components. It does not demonstrate that the programme changes the course of any eye disease.
  • The evidence for individual components is largely preclinical or of low certainty. The Cochrane review of acupuncture for glaucoma found the available studies insufficient to determine effectiveness, with very low-certainty evidence, and its literature search closed in November 2018. A systematic review of acupuncture for age-related macular degeneration rated the evidence low to very low. Botanical research relevant to retinal and optic-nerve disease is largely in cells and rodents.
  • Integrative care is not free of risk. Herbal products interact with medicines. Goji, or Lycium barbarum, is the subject of published case reports of potentiated warfarin effect. Acupuncture has a low rate of serious harm in trained hands but is not free of adverse events, and one prospective trial reported a transient rise in intraocular pressure immediately after eye-point sessions in glaucoma patients.
  • Traditional origin confers nothing. Any preparation intended to contact the eye faces exactly the ophthalmic standard set out above. The FDA states that there are no FDA-approved Ayurvedic products and that Ayurvedic products marketed to treat disease are illegally marketed in the United States; the agency has documented heavy metals and alkaloids in marketed preparations.
  • Apparent improvements in symptoms, acuity, fields or imaging can reflect learning effects, measurement variability, refractive change, ocular-surface improvement, natural fluctuation, concurrent standard care, or regression to the mean.
  • Individual responses vary.

Prospective, controlled research is the only thing that will resolve any of this, and it has not yet been done.

How to read a claim you find online

Five tests, in the order that eliminates the most claims fastest.

  1. Route. Was the research done by the same route as the product? A trial of an oral supplement says nothing about a drop.
  2. Species. Cells and rodents establish plausibility. They do not establish benefit in people. Shown to protect retinal cells almost always means cultured cells or mice.
  3. The exact product. An ingredient is not a product. Species, plant part, extraction method, dose, formulation and batch all change what is actually being given.
  4. The endpoint. Did something change that a person would notice, such as acuity, visual field, reading or quality of life, or did a marker move? A marker moving is a reason to run a trial, not a result.
  5. Who is telling you. Ask whether the party making the claim sells the thing. That includes us.

And one phrase settles it faster than any of them. Clinically proven is a claim about the state of the evidence, which makes it checkable in a way that efficacy claims are not. If a product has been tested in a controlled human trial, that trial has investigators, a registration number and a published result. Ask for all three. A long list of mechanism papers is not the same thing.

Questions worth taking to your eye doctor

  • Is this product sterile, and how is that maintained once the bottle is opened?
  • Has this specific product, not the ingredient and not an oral version, been tested in people with my condition?
  • What evidence is there that it reaches the part of my eye it is meant to help?
  • What would tell us it is not working, and at what point would we stop?
  • Does it interact with anything I already take, including blood thinners?
  • Does my ophthalmologist know I am using it?

Frequently asked questions

Are MSM eye drops FDA-approved?

No. The FDA states that there are no legally marketed ophthalmic drugs that contain MSM as an active ingredient.

Are all MSM eye drops contaminated?

That is not established. In 2023 the FDA found contamination in specific tested products and issued warning letters; a separate company recalled its MSM drops for non-sterility. Those findings concern the products tested. The broader issue is the absence of a legally marketed MSM ophthalmic drug and the limited direct human evidence.

Does MSM have any scientific support at all?

Yes, but mostly for oral use and mostly for musculoskeletal outcomes. The ocular animal studies used MSM chiefly as a permeability enhancer for a chelating agent, and in the raised-pressure model that combination did not lower intraocular pressure.

Has integrative eye care been shown to work better than MSM eye drops?

No. There is no head-to-head trial, and the complete NRT protocol has not been evaluated in controlled trials. The difference that can be described accurately is structural: a supervised programme can be individualized, screened for interactions, coordinated with standard care and measured objectively.

Can this replace my glaucoma drops, injections or surgery?

No. Integrative care is adjunctive. Continue the treatment and monitoring your ophthalmologist has prescribed unless that clinician changes the plan.

Do preclinical botanical studies prove human benefit?

No. They support biological plausibility and help design trials. Human benefit requires product-specific clinical research with a standardized formulation, dose, outcomes and safety monitoring.

Do MSM eye drops work?

No controlled human trial has tested an MSM eye drop for any eye condition, so there is no result to report in either direction. The animal work most often cited used MSM as a delivery aid for a different compound, and in the raised-pressure model that combination did not lower intraocular pressure. Absence of evidence is not proof that something fails. It means the question has not yet been asked properly.

What benefits are claimed for MSM eye drops?

Marketing typically claims reduced inflammation, softening of the lens in cataract, improved ocular circulation, clearer vision, or slowed progression of macular degeneration and glaucoma. Those claims are generally extrapolated from oral MSM studies on joint pain, or from laboratory work in cells and rodents. None has been demonstrated for an eye drop in people.

Do MSM drops help floaters or cataracts?

There is no evidence that they do. We found no study of any kind testing MSM for floaters. Floaters sit in the gel that fills the back of the eye, and nothing shows that a drop placed on the surface reaches it. For cataracts, the work usually cited is a 2011 study in diabetic rats and in lenses kept in culture, where drops of EDTA, a chelating agent, with MSM added to help it penetrate, reduced lens clouding. That tested a different compound, in rats, and no trial in people has followed. No eye drop has been shown to reverse a cataract; the National Eye Institute says surgery is the only way to get rid of one. A sudden shower of new floaters, flashes or a shadow across your vision needs same-day care. Our guides explain how to get rid of eye floaters and when cataract surgery is needed.

Can I make MSM eye drops at home?

Please do not. Recipes circulate online that involve dissolving MSM powder in distilled water or saline. Home preparation cannot achieve or maintain sterility, cannot control pH or osmolality, and cannot establish that the powder is free of contaminants. Powder sold for oral or industrial use is not manufactured to ophthalmic standards. The 2023 artificial-tear outbreak described above involved a commercially manufactured product that failed on sterility alone, and it was linked to four deaths and fourteen patients with vision loss.

Are liquid MSM eye drops safe?

Their safety has not been established. “Liquid MSM” can mean two different things: an oral liquid supplement meant to be swallowed, or drops sold for the eyes. Never put an oral liquid in your eyes, because it is not made to the sterile standard that eye drops must meet. Drops sold for the eyes are not FDA-approved either, and the products named in the 2023 recalls and FDA warning described above were MSM eye drops. If you have used them and notice pain, redness, discharge, light sensitivity or blurred vision, stop and see an eye doctor promptly.

Is MSM good for the eyes?

There is no good evidence that it is. We found no controlled human trial showing that MSM, taken by mouth or used as a drop, improves any eye condition. The ocular studies were in rats and used MSM to help a different compound penetrate the eye. Oral MSM research concerns joints and exercise recovery, not vision.

What are MSM drops for?

They are sold online for cataract, glaucoma, macular degeneration, dry eye and general "eye repair", but none of these uses is approved, and no controlled human trial supports them. Oral MSM supplements are a different product, sold mainly for joint pain. If dry eye is the problem, our guide to whether dry eyes can be cured permanently covers the treatments that have been tested.

What are the bad side effects of MSM?

Taken by mouth, MSM has few well-documented side effects; those reported include bloating, constipation, fatigue, headache and insomnia, and one case report linked MSM-containing supplements, taken together with several others, to acute angle closure, a glaucoma emergency. With drops, the main danger is contamination, because an infected cornea can threaten sight. Stop and seek care for pain, redness, discharge or blurred vision.

What should you not mix with MSM?

No drug interactions are well documented for oral MSM. That mostly reflects how little it has been studied, and it does not mean none exist. Never put oral MSM powder or liquid in your eyes, and do not add any MSM product alongside prescribed eye drops for glaucoma, inflammation or recovery after surgery without asking your eye doctor. Tell every clinician which supplements you take.

Has the FDA recalled MSM eye drops?

The FDA does not recall these products itself, but two companies have. In March 2023 Pharmedica USA recalled Purely Soothing 15% MSM Drops because they were not sterile. In August 2023 the FDA warned consumers not to buy or use Dr. Berne's MSM Drops 5% Solution or LightEyez MSM Eye Drops – Eye Repair after its testing found contamination, and Dr. Berne's then recalled its MSM drops. The FDA sent warning letters to Dr. Berne's in November 2023 and to LightEyez in February 2024.

If you were looking at MSM drops because standard care has stalled

That is the situation most people are in when they search for this. The honest position is that no drop, including ours if we sold one, has been shown to change the course of glaucoma, macular degeneration or retinal disease. What a supervised programme can offer is different: a review of what you already take, baseline measurements that are repeated on a schedule, and a clinician who will tell you when something is not working.

If you want to know whether that is appropriate for your condition, Am I a candidate? explains who Netra Restoration Therapy is and is not for, and the cost page lists every charge. Both are written to be read before you call.

When to get urgent care

Get emergency care now for sudden loss of vision, a curtain or shadow across your vision, severe eye pain or an eye injury. If a chemical gets in your eye, rinse it with clean water right away, for at least 20 minutes, while you get emergency help. If you have any new symptom after eye surgery, contact your surgeon right away, or go to the emergency room if you cannot reach them. Get an eye exam the same day for new flashes, a shower of new floaters or a red eye that is sensitive to light.

About this article

Published by Netra Eye Institute, which provides integrative eye care as a paid clinical service. This is not independent third-party product research. It is general education and not medical advice, a diagnosis, or a treatment recommendation for any individual. No programme or product described here has been shown in controlled trials to change the course of any eye disease. Regulatory statements are current as of 24 October 2026.

Sources

  1. U.S. Food and Drug Administration. What You Should Know About Eye Drops. Content current 15 June 2026.
  2. U.S. Food and Drug Administration. FDA Warns Consumers Not to Purchase or Use Certain Methylsulfonylmethane (MSM) Eye Drops Due to Contamination. 22 August 2023; content current 30 August 2023.
  3. Grossman MK, et al. Extensively drug-resistant Pseudomonas aeruginosa outbreak associated with artificial tears. Clin Infect Dis. 2024;79(1):6-14. Final case figures from the U.S. Centers for Disease Control and Prevention.
  4. Butawan M, Benjamin RL, Bloomer RJ. Methylsulfonylmethane: applications and safety of a novel dietary supplement. Nutrients. 2017;9(3):290.
  5. Zhang M, et al. Assessment of methylsulfonylmethane as a permeability enhancer for regional EDTA chelation therapy. Drug Deliv. 2009;16(5):243-248.
  6. Liu P, et al. Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure. Free Radic Biol Med. 2014;69:289-299.
  7. Zhang M, Shoeb M, Liu P, et al. Topical metal chelation therapy ameliorates oxidation-induced toxicity in diabetic cataract. J Toxicol Environ Health A. 2011;74(6):380-391.
  8. National Eye Institute. Cataracts. Updated 19 August 2026. link
  9. Hwang JC, Khine KT, Lee JC, Boyer DS, Francis BA. Methyl-Sulfonyl-Methane (MSM)-induced acute angle closure. J Glaucoma. 2015;24(4):e28-e30.
  10. Baudouin C, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334.
  11. Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24(2):66.
  12. Law SK, Wang L, Li T. Acupuncture for glaucoma. Cochrane Database Syst Rev. 2020;2(2):CD006030. Literature search closed November 2018.
  13. Sun W, et al. Effects of acupuncture on age-related macular degeneration: a systematic review and meta-analysis. PLoS One. 2023;18(3):e0283375.
  14. U.S. Food and Drug Administration. FDA Warns About Heavy Metal Poisoning Associated With Certain Unapproved Ayurvedic Drug Products. Updated 2 December 2025.
  15. Pharmedica USA LLC. Pharmedica USA LLC Issues Voluntary Worldwide Recall of Purely Soothing 15% MSM Drops Due to Non-Sterility. Company announcement posted by the U.S. Food and Drug Administration, March 2023. link
  16. Dr. Berne's Whole Health Products. Dr. Berne's Whole Health Products Issues Voluntary Nationwide Recall of Dr. Berne's MSM Drops 5% and 15% Solution, Castor Oil Eye Drops and MSM Mist. Company announcement posted by the U.S. Food and Drug Administration, 26 August 2023. link
  17. U.S. Food and Drug Administration. Warning letters to Dr. Berne's Whole Health Products (22 November 2023) and LightEyez Limited (15 February 2024).
  18. Drugs.com. Methylsulfonylmethane (MSM) (professional monograph: interactions, adverse reactions, toxicology). Accessed 24 October 2026. link

Full reference list, 84 peer-reviewed sources and 15 regulatory sources, all verified 22 August 2026, available on request.

More on nutrition and eye health

More From the Blog